In 2012, he said he discovered mistakes in two studies that were used to promote NiQuitin, an oral soluble nicotine film. Patients in the study were randomly given either a 2.5-mg dose of nicotine film (NiQuitin) or a 2-mg dose of nicotine lozenges.
The studies concluded that NiQuitin relieved cravings faster than nicotine lozenges or gum, and results were published in Psychopharmacology in April 2014.
Selmani says researchers mistakenly considered the products equivalent, despite the obvious difference in nicotine dosage. He also took issue with “deceptive” statistical analyses. According to the lawsuit complaint:
“GSK engaged in an illegal, deceptive [marketing] program worldwide to promote the use of NiQuitin, asserting without justification that NiQuitin was superior to existing nicotine treatment.”
When his immediate supervisors refused to make corrections to the errors, Selmani sent an email directly to the company’s CEO, warning that the study miscalculations have the “capacity to cause negative consequences and potential health and safety issues for the general public.”
Selmani accuses his managers of firing him in retaliation, violating state laws protecting whistleblowers who expose fraud and other wrongdoings. The lawsuit was flied in New Jersey Superior Court on January 6, Case No. MRS L-2995-15.
Need a Defective Drug Lawyer in Texas?
Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged.
Collen’s amazing success in the courtroom and well known dedication to his clients has earned him the recognition of his peers as one of The Top Trial Lawyers in Texas.”
The Clark Firm has assembled a team of trial lawyers with more than 100 years experience, participation in over 600 jury trials and $260 million in verdicts and/or settlements. Please use the form below to contact our Texas defective drug lawyers for a free lawsuit review.